Equities research analysts at StockNews.com started coverage on shares of NantHealth (NASDAQ:NH – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock.
NantHealth Stock Performance
Shares of NH opened at $0.28 on Monday. The company has a 50-day simple moving average of $0.33 and a 200-day simple moving average of $0.46. The firm has a market capitalization of $32.37 million, a P/E ratio of -0.55 and a beta of 2.06. NantHealth has a 52 week low of $0.17 and a 52 week high of $1.50.
NantHealth (NASDAQ:NH – Get Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($0.13) EPS for the quarter. The firm had revenue of $16.63 million for the quarter. As a group, equities analysts forecast that NantHealth will post -0.39 earnings per share for the current year.
Institutional Trading of NantHealth
NantHealth Company Profile
NantHealth, Inc, together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions.
- Get a free copy of the StockNews.com research report on NantHealth (NH)
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.